# Phase 2 Study of DKN-01 in Colorectal Cancer

> **NCT05480306** · PHASE2 · COMPLETED · sponsor: **Leap Therapeutics, Inc.** · enrollment: 188 (actual)

## Conditions studied

- Colorectal Cancer
- Colorectal Adenocarcinoma
- Colo-rectal Cancer
- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** DKN-01
- **DRUG:** FOLFIRI
- **DRUG:** Bevacizumab
- **DRUG:** FOLFOX

## Key facts

- **NCT ID:** NCT05480306
- **Lead sponsor:** Leap Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-30
- **Primary completion:** 2025-07-10
- **Final completion:** 2025-07-10
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05480306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05480306, "Phase 2 Study of DKN-01 in Colorectal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05480306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*